HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Cancer Research

• Publication date

  2013-05-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1541-7786.MCR-13-0040-TPMID 23723075PMCID PMC3778089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lysine acetylation: enzymes, bromodomains and links to different diseases.

  2012cited by this paper
• Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes

  2012cited by this paper
• Regulation of RAS oncogenicity by acetylation

  2012cited by this paper
• The histone deacetylase SIRT2 stabilizes Myc oncoproteins

  2012cited by this paper
• Succinate Dehydrogenase Is a Direct Target of Sirtuin 3 Deacetylase Activity

  2011cited by this paper
• PKC alpha regulates Sendai virus‐mediated interferon induction through HDAC6 and β‐catenin

  2011cited by this paper
• SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

  2011cited by this paper
• Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors

  2011cited by this paper
• Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

  2010cited by this paper
• Mammalian sirtuins: biological insights and disease relevance.

  2010cited by this paper
• Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer

  2009cited by this paper
• The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.

  2008cited by this paper
• Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin

  2007cited by this paper
• Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

  2005cited by this paper
• Cre-lox-regulated conditional RNA interference from transgenes.

  2004cited by this paper
• The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase.

  2003cited by this paper
• HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo

  2003cited by this paper
• In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation

  2002cited by this paper
• HDAC6 is a microtubule-associated deacetylase

  2002cited by this paper
• Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

  2000cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• p21ras is modified by a farnesyl isoprenoid.

  1989cited by this paper
• All ras proteins are polyisoprenylated but only some are palmitoylated.

  1989cited by this paper

• Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer

  2025influential citation
• Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches

  2025cites this paper
• Programmed Targeted Protein Degradation Via DNA Modularized Ligand

  2025cites this paper
• Acetylation and deacetylation dynamics in stress response to cancer and infections.

  2025cites this paper
• Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors

  2025cites this paper
• The role of acetylation and deacetylation in cancer metabolism

  2025cites this paper
• Research Progress of Biological Function and Prognosis of Colorectal Cancer in Sirtuins Family

  2024cites this paper
• A temperature-ultrasound sensitive nanoparticle delivery system for exploring central neuroinflammation mechanism in stroke-heart syndrome

  2024cites this paper
• Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.

  2024cites this paper
• Enlightening epigenetics: optochemical tools illuminate the path.

  2024cites this paper
• Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma

  2023cites this paper
• Curriculum vitae of HDAC6 in solid tumors.

  2023cites this paper
• In silico approach reveals N-(5-phenoxythiophen-2-yl)-2-(arylthio)acetamides as promising selective SIRT2 inhibitors: the case of structural optimization of virtual screening-derived hits

  2023cites this paper
• Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

  2023cites this paper
• Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation

  2023cites this paper
• Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

  2023cites this paper
• Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.

  2023cites this paper
• Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

  2023cites this paper
• Regulation of Ras-GTPase Signaling and Localization by Post-Translational Modifications

  2023influential citation
• Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review

  2023cites this paper
• The Potential of Senescence as a Target for Developing Anticancer Therapy

  2023cites this paper
• Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.

  2022cites this paper
• Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling

  2022cites this paper
• RAS: Circuitry and therapeutic targeting.

  2022cites this paper
• Tubulin deacetylase NDST3 modulates lysosomal acidification: Implications in neurological diseases

  2022cites this paper
• Recent Advances in PROTACs for Drug Targeted Protein Research

  2022cites this paper
• HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma

  2022cites this paper
• The role of ral signaling and post translational modifications (PTMs) of Ras in cancer

  2022cites this paper
• Sirtuins, healthspan, and longevity in mammals

  2021cites this paper
• Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers

  2021influential citation
• Sirtuin Modulators in Cellular and Animal Models of Human Diseases

  2021cites this paper
• Vorinostat (SAHA) and Breast Cancer: An Overview

  2021cites this paper
• Naturally occurring small molecule compounds that target histone deacetylases and their potential applications in cancer therapy

  2021cites this paper
• Emerging role of SIRT2 in non-small cell lung cancer

  2021influential citation
• Post-translational modification of RAS proteins.

  2021cites this paper
• Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification

  2021cites this paper
• PROTACs technology for targeting non-oncoproteins: Advances and perspectives.

  2021cites this paper
• Ras and Ras Signaling as a Therapeutic Target in Cancer

  2021cites this paper
• The bifunctional roles of sirtuins and their therapeutic potential in cancer

  2021cites this paper
• Ras sumoylation in cell signaling and transformation.

  2021cites this paper
• Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates

  2021cites this paper
• Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism

  2021cites this paper
• HDAC6 promotes growth, migration/invasion and self-renewal of rhabdomyosarcoma

  2020cites this paper
• Influence of Cholesterol on the Orientation of the Farnesylated GTP-Bound KRas-4B Binding with Anionic Model Membranes

  2020cites this paper
• Post-translational modification of KRAS: potential targets for cancer therapy

  2020cites this paper
• KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility

  2020cites this paper
• Biology, pathology, and therapeutic targeting of RAS.

  2020cites this paper
• E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation

  2020cites this paper
• Surtuin 1 as a potential prognostic biomarker in very elderly patients with colorectal cancer

  2020cites this paper
• QSAR studies on the human sirtuin 2 inhibition by non-covalent 7,5,2-anilinobenzamide derivatives

  2020cites this paper
• Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies

  2020cites this paper
• HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma

  2020cites this paper
• Unexpected small molecules as novel SIRT2 suicide inhibitors.

  2020cites this paper
• HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

  2020cites this paper
• RAS: Striking at the Core of the Oncogenic Circuitry

  2019cites this paper
• Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype

  2019cites this paper
• Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.

  2019cites this paper
• RETRACTED ARTICLE: Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1

  2019influential citation
• Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

  2019cites this paper
• Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

  2019cites this paper
• The sirtuin family in cancer

  2019influential citation
• Functional genetic variants within the SIRT 2 gene promoter in breast cancer

  2019cites this paper
• Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

  2019cites this paper
• Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

  2019cites this paper
• Regulation of large and small G proteins by ubiquitination

  2019cites this paper
• Immunohistochemistry and clinical value of sirtuin 2 in non-metastasized non-small cell lung cancer.

  2019cites this paper
• The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function

  2019cites this paper
• HDAC6 promotes self-renewal and migration/invasion of rhabdomyosarcoma

  2019cites this paper
• Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

  2018cites this paper
• Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy

  2018cites this paper
• Chemical Protein Degradation Approach and its Application to Epigenetic Targets.

  2018cites this paper
• Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms

  2018cites this paper
• Posttranslational Modifications of RAS Proteins.

  2018cites this paper
• Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice

  2018cites this paper
• New chemical tools for probing activity and inhibition of the NAD+-dependent lysine deacylase sirtuin 2

  2018cites this paper
• Opening the Selectivity Pocket in the Human Lysine Deacetylase Sirtuin2 - New Opportunities, New Questions.

  2018cites this paper
• The Current State of NAD+‐Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets

  2018cites this paper
• HDAC6 deacetylates ERK1

  2017cites this paper
• Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.

  2017cites this paper
• Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity

  2017cites this paper
• Activation of Ras by Post-Translational Modifications

  2017cites this paper
• Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.

  2017cites this paper
• A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation*

  2017cites this paper
• Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).

  2017cites this paper
• SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.

  2017cites this paper
• RAS ubiquitylation modulates effector interactions

  2017cites this paper
• HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma

  2017cites this paper
• Synthesis and Evaluation of Novel Benzofuran Derivatives as Selective SIRT2 Inhibitors

  2017cites this paper
• Sirtuins in Cancer – Emerging Role as Modulators of Metabolic Reprogramming

  2016cites this paper
• Insights into K-Ras 4B regulation by post-translational lysine acetylation

  2016cites this paper
• A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

  2016cites this paper
• The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions

  2016cites this paper
• Biology, Chemistry, and Pharmacology of Sirtuins.

  2016cites this paper
• Structure-Based Development of an Affinity Probe for Sirtuin 2.

  2016cites this paper
• K-Ras protein as a drug target

  2016cites this paper
• Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.

  2016cites this paper
• SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia

  2016cites this paper
• A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

  2016cites this paper
• FAM65B controls the proliferation of transformed and primary T cells

  2016cites this paper
• OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination

  2016cites this paper